Skip to main content

News & Events

  • Novozymes, which employs some 465 people at its North American headquarters in Franklinton, is buying Merck’s crop bioscience business, Milwaukee-based EMD/Merck Crop BioScience, for $275 million.
  • Research Triangle Park-based Icagen has begun clinical trials on a drug it’s developing with global giant Pfizer. The compound, dubbed Nav1.7, is being developed as a pain treatment. Icagen recently announced positive results in a Phase IIa clinical trial of its experimental asthma therapy, senicapoc, in the United Kingdom.
  • North Carolina is already a big player in the fast-growing nanotechnology world, according to a report in the online news site WRAL LocalTechWire.  Jim Roberts, director of membership services and fundraising for North Carolina’s Center of Innovation for Nanobiotechnology (COIN), wrote the guest article after he and others from the COIN staff returned from the Nanotechnology Summit held in Washington, D.C. last week.
  •  Research Triangle Park-based Tranzyme Pharma has named John Johnson, president of Lilly Oncology and senior vice president at Eli Lilly, as the new chairman of the board. Blue Cross Blue Shield of Delaware has named Burlington-based LabCorp and its DIANON Systems subsidiary to be its exclusive non-hospital commercial laboratory provider, beginning Feb. 1, 2011. More
  • Due to icy road conditions, the North Carolina Biotechnology Center will close Thursday, December 16 at 3 p.m. and open Friday, December 17 at 10 a.m.  The Piedmont Triad office will open at 1o a.m. on Friday.
  • The Biotechnology Center's RTP office will open at noon today because of lingering icy conditions from the  snow and frozen precipitation in the RTP area.  Our Western office is open at 10 a.m. The Piedmont Triad office is closed today, and you can reach the staff via e-mail. Check back for updates and pictures of our Hunt Annex in the snow.
  • The Triangle Global Health Consortium breakfast discussion that had been scheduled for Thursday morning at the North Carolina Biotechnology Center has been cancelled due to the threat of potentially dangerous wintry weather The meeting to discuss Pro-Poor Health Financinghad been planned for a 7:30 a.m. start on Dec. 16. Weather forecasters have been calling for snow in the Research Triangle area turning to rainy slush by Thursday afternoon, creating potentially hazardous traffic conditions.
  • Mere days after filing for federal approval to market a new rootworm-resistant corn, Syngenta Biotechnology Inc. has announced a corn rootworm deal with Dupont’s Pioneer Hi-Bred division that could produce $400 million for the Research Triangle Park company.
  • Current and former leaders and members of North Carolina Biotechnology Center boards and committees are among 17 people cited this week by the North Carolina Association for Biomedical Research for their contributions to the state’s life sciences . The non-profit Raleigh organization named the 17 “Distinguished Leaders in Bioscience Research and Development” for helping the state achieve top-three status in bioscience company development.
  • Robert Ingram, vice chairman of pharmaceuticals for GlaxoSmithKline who recently chaired the North Carolina Biotechnology Center's building committee, has been named chairman of the board of Dublin, Ireland-based Elan Corp. More  
  • Syngenta Biotechnology Inc. is seeking federal approval to market a new rootworm-resistant corn. The growing Research Triangle Park-based agribusiness has asked the United States Department of Agriculture for the go-ahead on a new trait Syngenta scientists have developed, dubbed Event 5307. The trait provides a new way to disrupt the digestive tracts of destructive corn rootworms as they eat.
  • A new advisory council has begun to explore the sky-high possibilities of North Carolina’s most down-to-earth business sector.  Agricultural leaders who are members of the North Carolina Agricultural Biotechnology Advisory Council have met for the first time at the North Carolina Biotechnology Center. The 21 leaders from across the state came together to explore ways to develop valuable new opportunities that can be harvested from North Carolina’s fertile agriculture and biotechnology fields.
  • Industry Expansions May Create 3,100 New Jobs By Barry Teater Vice President, Corporate Communications (Barry no longer works at the Center) North Carolina, already the world's leading center for contract research organizations, is entering a renaissance era of CRO company growth and job creation.
  • WINSTON-SALEM -- President Barack Obama today used North Carolina’s biotechnology successes as a platform for rallying Americans around a “new Sputnik moment” to reclaim U.S. scientific and educational superiority.
  •  Marjorie Benbow, JD, MBA, MSPH, executive director of the Biotechnology Center’s Greater Charlotte Regional Office, is profiled in the December 2010 issue of US Airways Magazine as one of the Top 20 Dynamic Women of Charlotte. More
  • North Carolina science educators and their students have a new way to stay informed about life-science businesses and activities around the state. The quarterly life science magazine Impact, published in Charlotte, is now being mailed free to science teachers, guidance counselors and career and technical-education coordinators in North Carolina public and private high schools.
  • Kenneth Tindall, Ph.D., senior vice president for science and business development at the North Carolina Biotechnology Center, has become chairman of the Southeast BIO trade organization.  
  • According to, TZYM will be the Nasdaq symbol for Tranzyme Pharma if the Securities and Exchange Commission approves its plans for a $75 million IPO. In the last few months, the company, which specializes in small molecule technology and potential drugs for stomach and intestinal disorders, has entered partnerships worth millions.
  • A biotechnology company from Cary took home the grand prize in an EARLY/Stage Company Shootout at the SEBIO 12th Annual Investor Forum in Atlanta earlier this month. The company, Vascular Pharmaceuticals, is developing novel therapeutic compounds for the treatment of diabetes associated complications. Attended by nearly 350 attendees, the event drew biotech professionals from all over the southeast.
  • Novan, a Research Triangle Park spinout from the University of North Carolina at Chapel Hill,  has raised $3.05 million from nine investors in a $3.9 million stock offering. The disclosure came in a filing with the U.S. Securities and Exchange Commission.


Subscribe to News & Events